Gan & Lee Pharmaceuticals Co Ltd (SHG:603087) — Stock Price

CN¥67.70 CNY
▼ -2.86% today

Gan & Lee Pharmaceuticals Co Ltd (SHG:603087) is currently trading at CN¥67.70 CNY, down 2.86% today. Over the past 52 weeks, shares have ranged between CN¥52.05 and CN¥79.62. This page tracks Gan & Lee Pharmaceuticals Co Ltd's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Gan & Lee Pharmaceuticals Co Ltd (603087) total market value.

Gan & Lee Pharmaceuticals Co Ltd (603087) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Gan & Lee Pharmaceuticals Co Ltd's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.

Gan & Lee Pharmaceuticals Co Ltd Income Statement — Revenue, Profit & Earnings by Year

Gan & Lee Pharmaceuticals Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CN¥4.05 Billion CN¥3.05 Billion CN¥2.61 Billion CN¥1.71 Billion CN¥3.61 Billion
Cost of Revenue CN¥978.95 Million CN¥777.15 Million CN¥724.70 Million CN¥443.93 Million CN¥399.90 Million
Gross Profit CN¥3.07 Billion CN¥2.27 Billion CN¥1.88 Billion CN¥1.27 Billion CN¥3.21 Billion
Research & Development CN¥646.97 Million CN¥541.05 Million CN¥501.02 Million CN¥562.47 Million CN¥474.59 Million
SG&A CN¥934.08 Million CN¥115.89 Million CN¥90.10 Million CN¥84.52 Million CN¥97.80 Million
Total Operating Expenses CN¥3.26 Billion CN¥1.64 Billion CN¥1.57 Billion CN¥1.84 Billion CN¥1.51 Billion
Operating Income CN¥793.63 Million CN¥631.54 Million CN¥315.29 Million CN¥-568.87 Million CN¥1.70 Billion
EBITDA — CN¥545.57 Million CN¥400.79 Million CN¥-479.87 Million CN¥1.57 Billion
EBIT — CN¥294.58 Million CN¥180.03 Million CN¥-675.68 Million CN¥1.39 Billion
Interest Expense CN¥231.14K CN¥291.87K CN¥1.35 Million CN¥2.38 Million CN¥4.30 Million
Income Before Tax CN¥1.23 Billion CN¥630.39 Million CN¥306.14 Million CN¥-582.47 Million CN¥1.70 Billion
Income Tax Expense — CN¥15.72 Million CN¥-34.09 Million CN¥-142.96 Million CN¥243.26 Million
Net Income CN¥1.14 Billion CN¥614.66 Million CN¥340.07 Million CN¥-439.52 Million CN¥1.45 Billion

Gan & Lee Pharmaceuticals Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Gan & Lee Pharmaceuticals Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CN¥12.63 Billion CN¥12.04 Billion CN¥11.72 Billion CN¥10.61 Billion CN¥10.85 Billion
Total Current Assets CN¥5.48 Billion CN¥3.79 Billion CN¥6.18 Billion CN¥5.66 Billion CN¥6.87 Billion
Cash & Equivalents — — — — —
Short-term Investments CN¥1.40 Billion CN¥1.50 Billion CN¥2.41 Billion CN¥1.64 Billion CN¥1.62 Billion
Net Receivables CN¥593.23 Million CN¥248.57 Million CN¥388.86 Million CN¥195.46 Million CN¥941.15 Million
Inventory CN¥1.01 Billion CN¥1.05 Billion CN¥860.51 Million CN¥648.65 Million CN¥651.33 Million
Property, Plant & Equipment — — — CN¥3.66 Billion CN¥2.60 Billion
Goodwill — — — — —
Total Liabilities CN¥998.57 Million CN¥988.45 Million CN¥972.52 Million CN¥1.02 Billion CN¥686.02 Million
Total Current Liabilities CN¥815.79 Million CN¥801.13 Million CN¥773.45 Million CN¥813.04 Million CN¥485.53 Million
Long-term Debt — — — — —
Net Debt — CN¥-899.47 Million CN¥-2.44 Billion CN¥-2.87 Billion CN¥-3.29 Billion
Total Stockholder Equity CN¥11.63 Billion CN¥11.05 Billion CN¥10.74 Billion CN¥9.59 Billion CN¥10.17 Billion
Retained Earnings CN¥7.31 Billion CN¥6.76 Billion CN¥6.57 Billion CN¥6.23 Billion CN¥6.84 Billion

Gan & Lee Pharmaceuticals Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Gan & Lee Pharmaceuticals Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CN¥784.28 Million CN¥537.31 Million CN¥427.69 Million CN¥296.68 Million CN¥1.08 Billion
Capital Expenditures CN¥926.09 Million CN¥440.80 Million CN¥553.06 Million CN¥983.44 Million CN¥692.08 Million
Free Cash Flow CN¥-141.81 Million CN¥96.51 Million CN¥-443.61 Million CN¥-686.76 Million CN¥386.09 Million
Investing Cash Flow — CN¥-262.03 Million CN¥-1.30 Billion CN¥-442.45 Million CN¥-498.13 Million
Financing Cash Flow — CN¥-300.71 Million CN¥754.70 Million CN¥-100.87 Million CN¥-228.93 Million
Dividends Paid CN¥597.53 Million CN¥420.55 Million — CN¥168.46 Million CN¥224.62 Million
Stock-Based Compensation — — — CN¥19.59 Million —
Depreciation CN¥303.42 Million CN¥257.45 Million CN¥225.26 Million CN¥200.34 Million CN¥184.88 Million
Change in Cash CN¥83.65 Million CN¥-26.38 Million CN¥-110.89 Million CN¥-242.44 Million CN¥348.43 Million

Gan & Lee Pharmaceuticals Co Ltd Earnings History — EPS Actual vs. Analyst Estimates

Track Gan & Lee Pharmaceuticals Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Apr 22, 2026 0.55 0.45 +22.22%
Oct 30, 2025 0.36 0.51 -29.41%
Aug 07, 2025 0.49 0.52 -5.77%
Apr 24, 2025 0.19 0.22 -13.64%
Oct 22, 2024 0.35 0.24 +45.83%
Aug 28, 2024 0.35 0.35 +0.00%
Apr 24, 2024 0.16 0.23 -30.43%
Apr 27, 2023 -0.05 — —